This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

These Two Low-Dollar Stocks Are Growing Fast

Editor's note: As part of our partnership with Nightly Business Report, TheStreet's David Peltier will join NBR Monday (check local listings) to look at two low-dollar stocks with great potential.

U.S. stocks are down seven of the past eight sessions as the second-quarter earnings season has started out with a whimper. That said, I firmly believe investors will seek out and pay for above-average growth when investor sentiment becomes more rational. I have uncovered two low-dollar stocks that are consistently growing faster than their peers and which could ultimately trade up toward the double digits when the market notices them.

DepoMed (DEPO), which is currently changing hands around $5.45. The company's core asset is its oral drug-delivery system, Acuform. The technology allows for extended and targeted release of a pill, which allows for improved dosing of a medicine.

DepoMed's lead product is Glumetza, which is prescribed for treating type 2 diabetes. Last fall, the company also released Gralise, which is a pain treatment for patients who have contracted shingles.

DepoMed also has a potential treatment for menopausal hot flashes that management will likely submit to the Food and Drug Administration (FDA) for approval later this year. In addition, the company has licensed Acuform to a few drug giants, including Merck (MRK), to produce extended-release versions of existing products.

With new products driving growth, DepoMed is expected to generate nearly 80% revenue growth in 2013. Even so, at current levels, the stock is nearly 20% off its April highs. The company has a debt-free balance sheet with $2.30 a share of cash and securities and is expected to return to profitability in 2013. As a result, the shares could move up toward the high-single digits over the coming quarters.

Switching gears to the energy sector, SandRidge Energy (SD) also appears attractive, as it is trading at $6.68 a share. The exploration-and-production firm's product mix is about half oil, half natural gas, and I believe the underlying commodity prices have bottomed out for the time being.

SandRidge's above-average growth outlook is extremely attractive. With locations in the Permian Basin and other energy hotspots, the company is on track to deliver 40% annual production growth in 2012.

Similar to DepoMed, SandRidge shares are currently trading 20% off their recent highs. But with visibility for several quarters of above-average production, I believe the stock can reclaim higher levels. Add in a recovery in energy prices, and SandRidge could ultimately trade back up toward the double digits.

David Peltier is a research associate at TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks. He also doesn't invest in hedge funds or other private investment partnerships. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Peltier appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs